0001683168-23-007108.txt : 20231012 0001683168-23-007108.hdr.sgml : 20231012 20231012180010 ACCESSION NUMBER: 0001683168-23-007108 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230914 FILED AS OF DATE: 20231012 DATE AS OF CHANGE: 20231012 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cockroft Bettina M. CENTRAL INDEX KEY: 0001900452 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39126 FILM NUMBER: 231323507 MAIL ADDRESS: STREET 1: C/O ANNEXON, INC. STREET 2: 180 KIMBALL WAY, SUITE 200 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 4/A 1 ownership.xml X0508 4/A 2023-09-14 2023-09-25 0 0001729427 CNS Pharmaceuticals, Inc. CNSP 0001900452 Cockroft Bettina M. C/O CNS PHARMACEUTICALS, INC 100 WEST LOOP SOUTH, SUITE 900 HOUSTON TX 77027 1 0 0 0 0 Option to purchase common stock 2.27 2023-09-14 4 A 0 6500 A 2033-09-14 Common Stock 6500 8599 D Option to purchase common stock 1.09 2023-09-21 4 A 0 9475 A 2033-09-22 Common Stock 9475 18074 D The stock options set forth in this table vest in 36 equal monthly installments. The stock option was approved by the compensation committee of the company's board of directors on August 4, 2023, subject to shareholder approval of the 2020 Stock Plan under which the option was granted. The shareholders of the company approved the plan at the company's annual meeting on September 14, 2023. The stock options were issued in connection with the reporting person's Board of Director services to the Company. The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date. This amendment is being filed solely to correct the number of shares of common stock underlying the reported option issued on September 21, 2023, and the total number of derivative securities owned following the reported transaction. /s/ Christopher Downs, Attorney-in-fact 2023-10-12